CAR T cell therapy cleared a toddler's chemotherapy-resistant liver cancer in two outpatient infusions, with no toxicity and ...

The FDA has cleared Curvebeam's module for measuring bone mineral density -  a key development in the company's commercial rollout ...

Some doctors and influencers say women shouldn’t wait until their 60s for a DEXA scan. Here’s what to consider before getting ...

Learn about an iguanodon that had an infected skin ulcer that spread to one of its leg bones, leaving behind signs of ...

Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly ...

Automated extraction of trabecular volumetric bone mineral density (vBMD) from thoracic CT scans showed reproducibility across diverse technical acquisition scenarios, supporting its feasibility for ...

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial The prespecified interim futility analysis was conducted ...

Umama Ali spent more time as a kid arguing with his brother over who caused the most chaos in GTA Vice City than doing homework, and he’s been unapologetically hooked on games ever since. That ...

DEAR DR. ROACH: I’m a woman of 54 with somewhat limited mobility due to back pain. Perhaps for this reason, my primary care physician ordered a DEXA scan in 2023 and again in 2026. I was alarmed when ...

MESA, AZ / ACCESS Newswire / July 7, 2026 / Medical Care Technologies, Inc. (OTC PINK:MDCE) today elaborated on the rigorous six-phase internal testing framework that has powered the encouraging ...

AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case for a Strensiq successor tipped to generate blockbuster sales. The company has yet to share ...

Complex Regional Pain Syndrome Type 1 carries an estimated 65,000 new U.S. diagnoses each year, yet the clinical trial infrastructure to study it rigorously has been almost nonexistent — which makes ...